A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer
1996

Immunotherapy for Breast Cancer Using Sialyl-Tn

Sample size: 23 publication Evidence: moderate

Author Information

Author(s): DW Miles, KE Towlson, R Graham, M Reddish, BM Longenecker, J Taylor-Papadimitriou, RD Rubens

Primary Institution: ICRF Clinical Oncology Unit, Guy's Hospital

Hypothesis

Does low-dose cyclophosphamide pretreatment enhance the immune response to sialyl-Tn-KLH with DETOX-B in patients with metastatic breast cancer?

Conclusion

The study found that low-dose cyclophosphamide can augment the immune response to sialyl-Tn in breast cancer patients, although measurable tumor responses were limited.

Supporting Evidence

  • All patients developed IgG and IgM responses to sialyl-Tn.
  • Two minor responses were noted in patients who received the active specific immunotherapy injections.
  • Levels of IgM antibodies were significantly higher in patients pretreated with cyclophosphamide.

Takeaway

Doctors tested a new treatment for breast cancer that uses a special vaccine and a medicine to help the immune system work better. They found that it helped some patients, but not everyone.

Methodology

Patients with metastatic breast cancer were randomized to receive a vaccine with or without cyclophosphamide pretreatment, and their immune responses and tumor responses were assessed.

Limitations

The study had a small sample size and limited measurable tumor responses.

Participant Demographics

Median age was 56 years, with a range of 36-73 years; most had prior treatments for metastatic disease.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication